Cytokinetics rise after heart disease drug meets main goal in late-stage study

Shares of drug developer Cytokinetics CYTK.O 5.2% to $33.80 premarket

Company says experimental heart disease drug, aficamten, helped significantly improve patients' exercise capacity compared to standard-of-care treatment in a late-stage study

RBC Capital Markets estimates a $900 mln opportunity for this indication by 2034 of their $3.9 bln total rev opportunity for aficamten

CYTK stock has tumbled 25% so far in May after the FDA delayed its review date for aficamten' marketing application to Dec

Overall, the stock has lost ~32% YTD